Trial Profile
Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms PEAR
- 08 Apr 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Apr 2020)
- 28 Apr 2020 Status changed from recruiting to active, no longer recruiting.
- 11 Jun 2019 Planned End Date changed from 1 Jun 2018 to 1 Dec 2021.